GlassScriptPhysician profile
Anna Khananian
NPI 1982137287
$6,070.09
in general payments reported to CMS, 2019-2025
32 companies · $2,130 in 2025
The $2,130 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $195 · 2022: $1,001 · 2023: $895 · 2024: $1,850 · 2025: $2,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,860 · Education: $14.98.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,859.92 |
| Education | $14.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,961.40 | 2021-2025 | Evenity, Tavneos, Krystexxa |
| Abbvie INC. | $674.44 | 2021-2025 | |
| Aurinia Pharma U.S., INC. | $524.01 | 2022-2025 | Lupkynis |
| Ucb, INC. | $475.05 | 2021-2025 | Cimzia, Bimzelx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $323.45 | 2022-2025 | Jardiance, Ofev, Cyltezo |
| Fresenius Kabi USA, LLC | $273.05 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Pfizer INC. | $205.79 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $200.80 | 2021-2025 | |
| Glaxosmithkline, LLC. | $198.47 | 2022-2025 | Benlysta, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $197.08 | 2024-2025 | Orencia |
| Bayer Healthcare Pharmaceuticals INC. | $124.61 | 2023-2025 | |
| Octapharma USA, INC. | $104.72 | 2023-2025 | Octagam Immune Globulin (Human) |
| Genzyme Corporation | $103.68 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $82.95 | 2023-2024 | |
| Dexcom, INC. | $82.83 | 2023-2025 | Dexcom G6 Transmitter |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $73.91 | 2024-2025 | Wainua |
| Radius Health, INC. | $49.58 | 2023-2025 | Tymlos |
| Genentech USA, INC. | $43.80 | 2025 | Gazyva, Actemra |
| Ascensia Diabetes Care US INC. | $41.94 | 2024 | |
| United Therapeutics Corporation | $40.05 | 2023-2024 | Tyvaso |
| Janssen Biotech, INC. | $34.91 | 2024 | Simponi Aria |
| Alexion Pharmaceuticals, INC. | $33.89 | 2024 | Strensiq |
| Xeris Pharmaceuticals, INC. | $29.79 | 2023-2024 | Gvoke Hypopen |
| Sandoz INC. | $26.84 | 2024 | Hyrimoz |
| Mannkind Corporation | $22.06 | 2023 | Afrezza |
| Biogen, INC. | $21.63 | 2024 | Skyclarys |
| Horizon Therapeutics Plc | $21.56 | 2022-2023 | Krystexxa |
| Kyowa Kirin, INC. | $21.53 | 2024 | Crysvita |
| Scilex Pharmaceuticals INC. | $21.43 | 2024 | |
| Medtronic, INC. | $20.80 | 2025 | Minimed 780g |
| Chiesi USA, INC. | $19.24 | 2024 | Mycapssa |
| Cequr Corporation | $14.80 | 2023 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Khananian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.